Maher Salamoon, MD


Department of Medical Oncology

Al-Bairouni University Cancer Center

Damascus, Syria


Maher Salamoon obtained his MD from the Faculty of Medicine from Damascus University School of Medicine (Syria) in 1998 then a Master degree in Medical Oncology and Hemato-Oncology from the Nuclear Medicine Centre, Damascus University in 2003, then a Post-doctoral study in Medical Oncology and Molecular Biology from Curie Institution in Paris (France). He did subspecialty in Non-Hodgkin Lymphoma and bone marrow transplant from Lyon-Sud University Hospital in Lyon (France) in 2006. He is the Head of Breast Cancer Department at Al Bairouni University Hospital 2008-2011, Damascus (Syria) and Head of Department of Soft Tissue Sarcoma at the same hospital (2011-2013). At present, he is the Team Leader of translational research at al Bairouni University Hospital and the Institute of biotechnology. He contributed more than 10 papers on translational research in several international oncology and hematology conference and 7 of them are in peer review, with more than 50 national and international publications. He was a speaker in several international and national meetings and reviewed more than 200 papers for international reputable journals.

Research Interest

Cell Culture
Cancer Biology
Health Education and Promotion
Clinical Oncology

Scientific Activities


1- Treatment of peripheral T-cell Lymphoma (PTCL) with an intensive protocol ACEP plus Ifosfamide showed an important progression free survival and overall survival rates. Journal of medical oncology, April 2013, 30:554.
2- High-dose Methotrexate, high-dose Cytarabine and Temozolomide for the treatment of Primary Central Nervous System Lymphoma (PCNSL),journal of medical oncology, August 2013, 30:690.
3-Phenotyping Of Cancer Stem Cells From Primary Breast Cancers: A Model For Evaluating The Response To Anti-Tumor Drugs M.I. Salamoon 1 M. Al Jamali 2 L. Youcef 2 I. Kasem 3 M. Bachour 1 1 Medical Oncology, Al Bairouni University Hospital, Damascus... Ann Oncol (2012) 23 (suppl 9): ix67-ix72 doi:10.1093/annonc/mds390.
4- Is It Possible To Tailor Breast Cancer Treatment By Using Breast Cancer Stem Cells As A Cell Model? Ann Oncol (2013) 24 (suppl 3): iii44 doi:10.1093/annonc/mdt086.6
5- metastatic breast cancer: getting the facts from peripheral blood. Annals of Oncology (2014) 25 (suppl_1): i21-i22. 10.1093/annonc/mdu069
6- Serum Caspase-3 and Caspase-7 as Predictive Factors of Response in Locally Advanced and Metastatic Breast Carcinoma , Hayma Hammoud, Jumana Saleh, Marroan Bachour, Maher Salamoon, Journal of Cancer TherapyVol.5 No.6(2014), Paper ID 46246DOI:10.4236/jct.2014.56067
7- Battah, Basem , salamoon M et al. “Serum CK18 as a Predictive Factor of Response to Chemotherapy in Locally Advanced and Metastatic Breast Cancer.” (2014).
8- Maher Salamoon. New Trends for the Treatment of Follicular Lymphoma in
Relapse: The Role of Type II Anti CD20. Sci J Blood Disord. 2017; 1(1): 1001.
9- Salamoon M (2018) BCL6/BCL2 and MYC Alterations Drawing the Gray Zone between Diffuse Large B-cell Lymphoma and Double, Triple Hit Lymphoma. J Mol Genet Med 12: 336. doi:10.4172/1747-0862.1000336
10- new insight into the treatment of follicular lymphoma: the role of Obinituzumab. Journal of hematology and oncology forecast. Salamoon M. New Insight for the Treatment of Follicular Lymphoma in Relapse: The Role of Obinutuzumab. J Hematol Oncol Forecast. 2018; 1(1):1002.
11- treatment of gray zone lymphoma, Jacobs journal of hematology issue 1, volume 1
12- her-2/ neu status in Syrian women with breast carcinoma : a Syrian cohort study of more than 10000 cases. Salamoon M*, Assad L, Ahmad F, Kenj M and Bachour M. Her-2/neu Status in Syrian Women with Breast Carcinoma: A SyrianCohort Study of more than 10000 Cases. Madridge J Can Stu Res. 2018; 2(1): 59-63. doi: 10.18689/MJCSR-1000109
13- A giant fibrovascular polype regurgitating out side the mouth upon coughing. Mustafa A, Khani RA, Salamoon M (2017) A Giant Fibrovascular Polyp Regurgitating Outside the Mouth upon Coughing. J Clin Epigenet. Vol.3 No.4:48
14- Targeting EGFR T790M in Advanced Adenocarcinoma of the Lung. Salamoon M. Targeting EGFR T790M in Advanced Adenocarcinoma of the Lung. Clin Oncol. 2018; 3: 1427.

Chapter book:
1-B-cell lymphoma treatment : present and future , Lambert academic publishing, code: 978-613-7-37849-6 will be on Amazon by feb.2019 (4 chapters)
2-Temozolomide: uses and adverse events: published by nova scientific publisher , new yourk will be available on Amazon by march.2019 (7 chapters)
3- 6 chapters in the book of: Cyclophosphamide: Clinical Pharmacology, Uses and Potential Adverse Effects.
Published by nova publishers, new York 2015
Chapter 1: Alkylating Agents
(Obeida Khalife, Muhammad Muhammad, Mazen Kenj and Maher Salamoon, Department of Medical Oncology; Kenj Cytogenetic Lab, and Department of Hematology, Al Bairouni University Cancer Center, Damascus, Syria)
Chapter 2: Cyclophosphamide in Hematological Malignancies
(Saurabh Chhabra, Rishi Agarwal, Zartash Gul and Muneer H. Abidi, Medical University of South Carolina, Charleston SC, USA and others)
Chapter 3: Treatment of Peripheral T-Cell Lymphoma with an Intensive Protocol ACEP (Adriamycin, Cyclophosfamide, Etoposide and Prednisolone) and Ifosfamide Showing a Good Overall Survival Rate at 7 Years
(Maher Salamoon, Marouane Bachour, Taisir Hussein and Mazen Kenj, Al Bairouni University Hospital, Department of Hematology and Medical Oncology; Tishreen Hospital, Department of Pathology, and Mazen Kenj Laboratory, Molecularbiology Section, Damascus, Syria)
Chapter 4: Improving Cancer Micro-Environment in Breast Cancer with Bone Metastasis through Chemopriming with High-Dose Cyclophosphamide and Mesenchymal Stem Cells Mobilization
(Mazen Kenj and Maher Salamoon, Kenj Lab, and Department of Medical Oncology, Al Bairouni University Cancer Center, Damascus, Syria)
Chapter 5: Oral Cyclophosphamide in Combination with Aromatase Inhibitors Can Control Bone Pain in Breast Cancer with Painful Bone Metastasis
(Maher Salamoon, Al Bairouni University Cancer Center, Damascus, Syria)
Chapter 6: High-Dose Cyclophosphamide can Replace Ifosfamide in Metastatic Soft Tissue Sarcoma in Case of Ifosfamide Shortage
(Maher Salamoon, Al Bairouni University Cancer Center, Damascus, Syria)
Chapter 7: Cyclophosphamide–Induced Hemorrhagic Cystitis
(Muhammad Muhammad, Obeida Khalife, Mazen Kenj and Maher Salamoon, Department of Medical Oncology, Al Bairouni University Cancer Center, and Kenj Cytogenetic Lab, Damascus, Syria)

Join as a Editor